New Nanomedicine Made from Phytic Acid Holds Potential for Treating Liver Disease Linked to Poor Metabolism

Researchers have developed a phytic acid-based nanomedicine that targets mTOR to treat metabolic dysfunction-associated steatohepatitis.

CePA, a cerium-phytic acid complex, demonstrates liver-targeted mTOR inhibition to alleviate metabolic dysfunction-associated steatohepatitis (MASH) in high-fat diet-fed mice.
The research focused on the antioxidant and anti-inflammatory properties of cerium and phytic acid, showing potential in treating liver diseases due to their high efficiency and safe mTOR inhibition capacity.
CePA complex successfully reduces fat accumulation and progression of MASH in mice through targeted mTOR inhibition and improved lipid metabolism regulation.
In vitro studies with human and mouse hepatocytes demonstrate CePA’s ability to inhibit lipid metabolism by blocking mTOR signaling pathways and improving inflammatory responses.
CePA treatment not only protects against hepatic steatosis, lipid-related damage, and fibrosis in MASH but also shows promise in providing a new approach for treating various liver diseases by regulating chemical modifications of hepatocytes.

Report from NASEM finds disparities in healthcare access for many Americans